Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NVNO 
enVVeno Medical Corp (NVNO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: NVNO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.5
1 Year Target Price $12.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.43% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.53M USD | Price to earnings Ratio - | 1Y Target Price 12.5 |
Price to earnings Ratio - | 1Y Target Price 12.5 | ||
Volume (30-day avg) 1 | Beta 0.88 | 52 Weeks Range 0.67 - 5.62 | Updated Date 09/17/2025 |
52 Weeks Range 0.67 - 5.62 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.59% | Return on Equity (TTM) -64.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -16729704 | Price to Sales(TTM) - |
Enterprise Value -16729704 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.87 | Shares Outstanding 19247100 | Shares Floating 16441293 |
Shares Outstanding 19247100 | Shares Floating 16441293 | ||
Percent Insiders 0.84 | Percent Institutions 29.88 |
Upturn AI SWOT
enVVeno Medical Corp
Company Overview
History and Background
enVVeno Medical Corp, formerly known as AngioDynamics, Inc., was founded in 1984. It has evolved from a focus on angioplasty to a broader range of minimally invasive medical devices. Recent rebranding (change in ticker from ANGO to NVNO) reflects a strategic shift towards venous disease.
Core Business Areas
- Venous Disease: Develops and markets products for the treatment of venous disorders, including chronic venous insufficiency and deep vein thrombosis. This is their core focus now.
- AngioDynamics Diversified: Includes products for peripheral vascular disease, thrombus management, and other surgical areas. This segment is being de-emphasized as they move towards venous disease. Revenue is declining in this segment.
Leadership and Structure
Michael J. Carrel is the President and CEO. The company has a typical corporate structure with a board of directors and executive leadership team overseeing various departments (R&D, Sales, Marketing, etc.).
Top Products and Market Share
Key Offerings
- VenoValve: A surgically implantable venous valve designed to treat chronic venous insufficiency (CVI). VenoValve is the company's main future revenue driver. Market share is currently low as it is pending FDA approval. Key competitors include companies offering compression therapy and other interventional venous solutions such as Medtronic.
- BioFlo PICC: A peripherally inserted central catheter (PICC) with a unique anti-thrombogenic coating. This product contributes significantly to current revenue but is part of the divesting Diversified segment. Competitors include BARD Access Systems (BDX), Teleflex (TFX), and Smiths Medical.
Market Dynamics
Industry Overview
The market for venous disease treatment is growing due to aging populations and increased prevalence of conditions like CVI and DVT. The medical device industry is competitive, with a mix of large players and smaller, specialized companies.
Positioning
enVVeno Medical Corp is positioning itself as a leader in innovative venous solutions, particularly with VenoValve, attempting to displace standard-of-care (compression therapy). It faces competition from established medical device companies.
Total Addressable Market (TAM)
The estimated TAM for venous disease treatment is multi-billion dollars. The CVI market alone is substantial. EnVVeno is positioned to capture a portion of this TAM with VenoValve, contingent on successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Focus on innovative venous solutions (VenoValve)
- Existing distribution network and customer relationships
- Experienced management team
- Proprietary technology in some product lines
Weaknesses
- Dependence on VenoValve approval for future growth
- Limited financial resources compared to larger competitors
- Declining revenue in existing product lines
- Small market capitalization
Opportunities
- FDA approval and commercialization of VenoValve
- Expansion into new geographic markets
- Development of new venous disease treatments
- Strategic partnerships or acquisitions
Threats
- Delays or failure in VenoValve clinical trials or regulatory approval
- Competition from established medical device companies
- Pricing pressures and reimbursement challenges
- Changes in healthcare regulations
Competitors and Market Share
Key Competitors
- MDT
- BSX
- ABT
Competitive Landscape
enVVeno Medical Corp is significantly smaller than its competitors. Its advantage lies in its focus on innovative venous solutions, but it faces challenges in competing with larger companies with greater resources and established market positions.
Major Acquisitions
Navilyst Medical
- Year: 2012
- Acquisition Price (USD millions): 372
- Strategic Rationale: Expanded AngioDynamics' product portfolio in vascular access and fluid management.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to strategic shifts and challenges in existing product lines.
Future Projections: Future growth is heavily dependent on VenoValve approval and commercial success. Analyst estimates are highly variable, ranging from modest to substantial growth depending on VenoValve's performance.
Recent Initiatives: The rebranding to enVVeno Medical Corp and the focus on venous disease represent recent strategic initiatives. The company is investing heavily in VenoValve clinical trials and pre-commercialization activities.
Summary
enVVeno Medical Corp is a high-risk, high-reward company transitioning to focus on venous disease treatment with its innovative VenoValve. Its future hinges on successful clinical trials and regulatory approval. While the company faces competition from larger players, its specialized focus and potential for market disruption could drive significant growth if VenoValve is successful. Its small size and limited resources are risks to watch for.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Press Releases
- Company Investor Presentations
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About enVVeno Medical Corp
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2018-05-31 | CEO & Director Mr. Robert A. Berman | ||
Sector Healthcare | Industry Medical Devices | Full time employees 37 | Website https://www.envveno.com |
Full time employees 37 | Website https://www.envveno.com | ||
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.